Torin 1 (Synonyms: Torin1;Torin-1) |
Catalog No.GC10131
One-Click Copy Product Info
|
Torin 1 is a potent ATP-competitive mammalian target of rapamycin (mTOR) inhibitor with an IC50 value of 3nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1222998-36-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Torin 1 is a potent ATP-competitive mammalian target of rapamycin (mTOR) inhibitor with an IC50 value of 3nM[1]. Torin 1 inhibits both mTORC1/2 complexes with IC50 values between 2 and 10nM[2]. Torin 1 is a potent autophagy inducer[3].
In vitro, treatment of glioblastoma (GB) LN-18 cells with Torin 1 (300, 1000nM) for 24h dose-dependently inhibited cell proliferation and migration and significantly inhibited cell entry into the S phase[4]. Treatment of S. pombe cells with Torin 1 (25μM) for 24h inhibited cell growth but did not cause cell death or G1 phase arrest[5].
In vivo, oral treatment of mice with dextran sulfate sodium (DSS)-induced colitis with Torin 1 (10, 20mg/kg) for 6 days significantly reduced pathological damage in the colon tissue and inhibited the production of proinflammatory cytokines in mice[6]. Torin 1 (400nM, 0.5μL) injected bilaterally into the insular cortex (IC) of nerve-injured rats significantly alleviated neuropathic pain and inhibited the increase in phosphorylated p70S6K (p-p70S6K) levels[7].
References:
[1] Thoreen C C, Kang S A, Chang J W, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1[J]. Journal of Biological Chemistry, 2009, 284(12): 8023-8032.
[2] Sun S Y. mTOR kinase inhibitors as potential cancer therapeutic drugs[J]. Cancer letters, 2013, 340(1): 1-8.
[3] Xu S, Li L, Li M, et al. Impact on autophagy and ultraviolet B induced responses of treatment with the MTOR inhibitors rapamycin, everolimus, torin 1, and pp242 in human keratinocytes[J]. Oxidative medicine and cellular longevity, 2017, 2017(1): 5930639.
[4] Amin A G, Jeong S W, Gillick J L, et al. Targeting the mTOR pathway using novel ATP-competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma[J]. International journal of oncology, 2021, 59(4): 83.
[5] Atkin J, Halova L, Ferguson J, et al. Torin1-mediated TOR kinase inhibition reduces Wee1 levels and advances mitotic commitment in fission yeast and HeLa cells[J]. Journal of cell science, 2014, 127(6): 1346-1356.
[6] Liu T, Zheng S, Guo P. Effect of Torin 1 on suppressing inflammation in mice with dextran sodium sulfate-induced colitis[J]. Int J Clin Exp Med, 2017, 10(3): 4723-4731.
[7] Choi S, Kim K, Cha M, et al. mTOR signaling intervention by Torin1 and XL388 in the insular cortex alleviates neuropathic pain[J]. Neuroscience Letters, 2020, 718: 134742.
| Cell experiment [1]: | |
Cell lines | LN-18 cells |
Preparation Method | Cells were treated with two doses (300 and 1000nM) of Torin 1, Torin 2, or XL388 for 24h, and then MTT assay was performed to measure cell proliferation. |
Reaction Conditions | 300, 1000nM; 24h |
Applications | Cell proliferation was significantly inhibited by Torin 1 in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | C57BL/6 mice |
Preparation Method | Mice were given free access to water containing Dextran sulfate sodium (DSS) for 6 days. The mice were randomly assigned to control, Torin 1 (20mg/kg)-treated, DSS-treated, Torin 1 (10mg/kg) +DSS-treated and Torin 1 (20mg/kg)+DSS-treated groups. Torin-1 as a suspension in 20% N-methyl-2-pyrrolidone/40% PEG400/40% water, orvehicle was delivered intragastrically once per day for 6 days from the first day, respectively. |
Dosage form | 10, 20mg/kg for 6 days; p.o. |
Applications | Torin 1 treatment significantly attenuated body weight loss and reduced the mortality induced by DSS. Torin 1 prevented DSS-induced colonic pathological damage, inhibited the production of pro-inflammatory cytokines in colon tissues. |
References: | |
| Cas No. | 1222998-36-8 | SDF | |
| Synonyms | Torin1;Torin-1 | ||
| Chemical Name | 1-[4-(4-propanoylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-9-quinolin-3-ylbenzo[h][1,6]naphthyridin-2-one | ||
| Canonical SMILES | CCC(=O)N1CCN(CC1)C2=C(C=C(C=C2)N3C(=O)C=CC4=CN=C5C=CC(=CC5=C43)C6=CC7=CC=CC=C7N=C6)C(F)(F)F | ||
| Formula | C35H28F3N5O2 | M.Wt | 607.64 |
| Solubility | <1.22mg/mL in DMSO, ≥ 2.42 mg/mL in EtOH with ultrasonic and warming | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6457 mL | 8.2286 mL | 16.4571 mL |
| 5 mM | 329.1 μL | 1.6457 mL | 3.2914 mL |
| 10 mM | 164.6 μL | 822.9 μL | 1.6457 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 21 reference(s) in Google Scholar.)